Alzamend Neuro, Inc. (ALZN)

$0.9

-0.03 (-3.69%)
Rating:
Recommendation:
-
Symbol ALZN
Price $0.9
Beta 0.000
Volume Avg. 0.80M
Market Cap 83.717M
Shares () -
52 Week Range 0.801-12.13
1y Target Est -
DCF Unlevered ALZN DCF ->
DCF Levered ALZN LDCF ->
ROE -92.10% Strong Sell
ROA -78.44% Strong Sell
Operating Margin -
Debt / Equity 3.90% Neutral
P/E -
P/B 7.08 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ALZN news


Mr. Milton Charles Ault III
Healthcare
Biotechnology
NASDAQ Capital Market

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline includes AL001, an ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's and other neurodegenerative diseases, and psychiatric disorders; and AL002, a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.